×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder

Jason M. Broderick
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
Jason Harris
According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.
Brielle Urciuoli
Actress Marilu Henner spoke with CURE about her husband's journey with cancer and the importance of having the difficult conversations.
Angelica Welch
Edward Messing, M.D., discusses his recent paper which explored a possible way to reduce recurrence in some patients with bladder cancer.
Allie Casey
Though deemed "safer" than normal cigarettes, electronic cigarettes may still pose a risk for bladder cancer.
Danielle Bucco
Arjun V. Balar, M.D., discusses Keytruda's impact on the treatment of urothelial carcinoma.
Jason M. Broderick
Keytruda (pembrolizumab) was granted an approval by the Food and Drug Administration (FDA) to treat some patients with locally advanced or metastatic urothelial carcinoma. 
Sponsored Content by Genentech, a Member of the Roche Group
Bladder cancer is the sixth most common cancer in the U.S.
Jason M. Broderick
The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Jason M. Broderick
The Food and Drug Administration has granted accelerated approval for durvalumab for treatment of patients with bladder cancer. 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable